A Phase 1 Study of Dabrafenib in Combination with Lapatinib in BRAF Mutant Thyroid Cancer (NCI #9354)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Lapatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- 12 Aug 2019 Planned number of patients changed from 18 to 21.
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Results (n=21) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.